Evidence map›Paper›PMID 40340262›Full record

ArticleCancer research and treatment2026

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry.

Hee Young Ju, Hyoung Soo Choi, Hyeon Jin Park, Keon Hee Yoo, Chuhl Joo Lyu, Ho Joon Im, Min Kyoung Kim, Yeung-Chul Mun, Joon Ho Moon, Sung-Soo Yoon and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hee Young JuDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hyoung Soo ChoiDepartment of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Hyeon Jin ParkCenter for Pediatric Cancer, Department of Pediatrics, National Cancer Center, Goyang, Korea.
Keon Hee YooDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chuhl Joo LyuDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Ho Joon ImDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Min Kyoung KimDepartment of Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Yeung-Chul MunDepartment of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
Joon Ho MoonDepartment of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Eunyoung LeeDepartment of Internal Medicine, Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea.
Jae Hoon LeeDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Je-Hwan LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
So Young ChongDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
June-Won CheongDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Seunghyun WonMedical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Korean Society of Blood and Marrow Transplantation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChronic myeloid leukemia (CML) in children, adolescents, and young adults is rare and differs from older adults. This study evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in young Korean CML patients during the tyrosine kinase inhibitor (TKI) era. MATERIALS AND

methodsA retrospective analysis of 35 CML patients aged < 40 years who underwent allogeneic HSCT from 2009 to 2019 was conducted using Korean Blood and Marrow Transplantation Registry data. Patients were grouped by age < 20 years at HSCT (group 1, n=15) and 20-40 years at HSCT (group 2, n=20). Survival outcomes including overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS) were analyzed using the Kaplan-Meier method.

resultsThe median time between diagnosis and HSCT was 8.9 months. All the patients achieved engraftment but platelet recovery was significantly slower in group 1 (p=0.034). Acute and chronic graft-versus-host disease occurred in 54.3% and 34.3%, respectively. Five-year OS, RFS, and EFS rates of total patients were 66.8%, 50.8%, and 47.6%, with better OS was observed in group 1 by multivariable analysis (p=0.048). Disease status at HSCT was a significant predictor of OS (p=0.028), RFS (p=0.003), and EFS (p=0.004). Disease progression occurred in 13 out of 35 patients (37.1%); treatment-related mortality accounted for 63.6% of deaths (7 out of 11).

conclusionWhen performed at a younger age, allogeneic HSCT result in superior outcome in CML. Achieving remission before HSCT is critical for improved outcomes, highlighting the importance of pretransplant remission via optimal TKI strategies and minimal residual disease monitoring.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdolescentAdultChildChild, PreschoolFemaleGraft vs Host DiseaseHumansMaleRegistriesRepublic of KoreaRetrospective StudiesTransplantation, HomologousTreatment OutcomeProtein Kinase InhibitorsTyrosine Kinase InhibitorsChildChronic myeloid leukemiaHematopoietic stem cell transplantationTreatment outcomesTyrosine kinase inhibitorsYoung adult

Identifiers

PMID40340262
PMCPMC13093028

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.